answer text |
<p>The Department is continuing negotiations for the supply of the meningococcal B
vaccine Bexsero<sup>®</sup> with the manufacturer Novartis with a view to securing
a cost-effective price as recommended by the Joint Committee on Vaccination and Immunisation.</p><p>
</p><p> </p><p> </p><p>Plans for inclusion of the Bexsero<sup>®</sup> in the routine
infant immunisation programme will depend on the outcome of these negotiations, which
will be completed as quickly as practicable.</p><p> </p>
|
|